December 30, 2014 +44 (0)20 7025 7911 [email protected]

Welcome to Volution Immuno Pharmaceuticals

Volution Immuno Pharmaceuticals (VIP) Ltd is a private, Swiss-based, clinical stage biotechnology company. The company is focused on developing anti-complement and anti-inflammatory molecules as treatments for a wide range of rare and orphan conditions in the autoimmune and inflammatory diseases sectors.

VIP’s lead molecule, Coversin, is a second generation complement inhibitor which acts on complement C5 preventing release of C5a and formation of C5b – 9, the membrane attack complex (MAC). Complement C5 inhibition is growing in importance in a wide range of autoimmune diseases including paroxysmal nocturnal haemoglobinuria (PNH), myasthenia gravis, Guillain Barré syndrome and in conditions such as antibody mediated transplant rejection.

VIP is a clinical stage biopharmaceutical company planning Phase II/III clinical trials in a number of conditions in Europe and North America from early 2015.

VIP has an experienced management team and is owned by the principals of RPC Healthcare ( www.healthcarecapitalpartners.com ). Its early term clinical targets fall into four major disease areas:

  • Haematology
  • Neurology
  • Nephrology
  • Ophthalmology
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.